Home > Science > New painkiller provides pain relief for 24 hours with a single doseNew painkiller provides pain reli

New painkiller provides pain relief for 24 hours with a single doseNew painkiller provides pain reli

Added: (Tue Oct 02 2001)

Pressbox (Press Release) - 3 October 2001 - Merck Sharp & Dohme Limited (MSD) today launches a new painkiller which provides powerful pain relief for up to 24 hours at a time with a single dose. VIOXX®ACUTE▼ contains rofecoxib, which has been shown to be as fast and effective as some conventional NSAIDs or a paracetamol and codeine combination1,2. VIOXX®ACUTE offers rapid relief from pain (usually within 45 minutes) that can last throughout both day and night.

VIOXXâACUTE may be particularly helpful for the many people whose painful conditions wake them during the night, including those suffering with dental pain, musculo-skeletal pain and period pain. It also offers a convenient once-daily alternative to those sufferers who may be struggling to get through the working day by taking traditional painkillers every 4-6 hours.

VIOXXâACUTE can deliver powerful relief of acute pain. Studies on rofecoxib, the active ingredient in this new painkilling tablet, have been conducted in patients suffering with a variety of painful conditions. One study in patients who had undergone dental surgery3 demonstrated that a single dose of rofecoxib 50 mg provides more pain relief over six hours than codeine 60 mg/paracetamol 600 mg. At the same time, substantially more people taking VIOXXâACUTE rated it as very good (33%) or excellent (15%) compared with those who took codeine/paracetamol combinations (10% and 4% respectively)3.

Studies in patients who have undergone surgery for orthopaedic complaints or back conditions have demonstrated that the pain relief obtained by taking VIOXXâACUTE can last up to 24 hours4,5.

Acute pain is one of the most frequent reasons for seeking medical help6. A 1998 UK survey showed that 2 out of every 5 adults experienced back pain lasting more than one day in a twelve month period, with nearly 40% of these visiting their doctor’s surgery as a result7. Period pain (primary dysmenorrhoea) similarly causes severe disruption to everyday life, with some 60% of young women saying that period pain causes them to cut back on their social or sporting activities8. And sporting activities themselves can cause significant incapacitation – a 1995 survey of sports and exercise-related injury estimated that 19.3 million new sports injuries occur in England & Wales alone every year9 - and this is likely to have increased since this last large-scale study was undertaken. Nearly half of these injuries (45%) are strains or sprains, with a further 18% classified as “unspecified pain”. A quarter of all injuries require medical treatment – most commonly from the family doctor, although 7% result in attendance at a hospital Accident & Emergency department.

- ends -


Notes to editors:
VIOXXâACUTE (rofecoxib) is licensed for the relief of acute pain and treatment of primary dysmenorrhoea, and is available on prescription in two strengths, an initial dose of rofecoxib 50mg once daily, following by subsequent doses of either 25 mg or 50 mg once daily as required.

Rofecoxib is the first of a new class of non-steroidal anti-inflammatory drugs (NSAIDs), COXIBs, to be available in the UK. It was initially designed to provide pain relief for osteoarthritis (OA) sufferers comparable to high dose NSAIDs, but with a significantly lower incidence of serious gastrointestinal (GI) events such as perforations, ulcers and bleeds10,11.


References:
1. Morrison B. Clin Ther 1999; 21(6): 943-953
2. Malmstrom K. Clin Ther 1999; 21(10): 1653-1663
3. Data on file, Merck Sharp & Dohme
4. Reicin A. Am J Orthopedics 2001; 40-48
5. Reuben SS. Anesth Analg 2000; 91: 1221-1225
6. Bonica JJ. The management of pain, 3rd ed. Philadelphia: Lea and Febigar, 1990: 222-254
7. Department of Health 1998. The Prevalence of Back Pain in Great Britain
8. Johnson J. J of Adolescent Healthcare 1988; 9: 398-402
9. Nicholl JP. Br J Sports Med vol 29, no 4, p 232-238
10. Hawkey, C.J. Lancet 1999, 353: 307–14
11. Langman MJ et al. JAMA 1999; 282: 1921-1928


For further media information, please contact:

Galliard Healthcare Communications
Ruth Ashton Nicole Barnard
tel: 020 7420 3287 tel: 020 7420 3284
mob: 07989 558041 email: nbarnard@galliardhealth.com
email: rashton@galliardhealth.com

Merck Sharp & Dohme Limited
Rachelle Michaels
tel: 01992 452470
mob: 07974 444402
email: rachelle_michaels@merck.com


For health professional and patients’ enquiries, please contact:

Merck Sharp & Dohme Limited
Medical Information Department
Tel: 01992 467272

3 October 2001 - Merck Sharp & Dohme Limited (MSD) today launches a new painkiller which provides powerful pain relief for up to 24 hours at a time with a single dose. VIOXX®ACUTE▼ contains rofecoxib, which has been shown to be as fast and effective as some conventional NSAIDs or a paracetamol and codeine combination1,2. VIOXX®ACUTE offers rapid relief from pain (usually within 45 minutes) that can last throughout both day and night.

VIOXXâACUTE may be particularly helpful for the many people whose painful conditions wake them during the night, including those suffering with dental pain, musculo-skeletal pain and period pain. It also offers a convenient once-daily alternative to those sufferers who may be struggling to get through the working day by taking traditional painkillers every 4-6 hours.

VIOXXâACUTE can deliver powerful relief of acute pain. Studies on rofecoxib, the active ingredient in this new painkilling tablet, have been conducted in patients suffering with a variety of painful conditions. One study in patients who had undergone dental surgery3 demonstrated that a single dose of rofecoxib 50 mg provides more pain relief over six hours than codeine 60 mg/paracetamol 600 mg. At the same time, substantially more people taking VIOXXâACUTE rated it as very good (33%) or excellent (15%) compared with those who took codeine/paracetamol combinations (10% and 4% respectively)3.

Studies in patients who have undergone surgery for orthopaedic complaints or back conditions have demonstrated that the pain relief obtained by taking VIOXXâACUTE can last up to 24 hours4,5.

Acute pain is one of the most frequent reasons for seeking medical help6. A 1998 UK survey showed that 2 out of every 5 adults experienced back pain lasting more than one day in a twelve month period, with nearly 40% of these visiting their doctor’s surgery as a result7. Period pain (primary dysmenorrhoea) similarly causes severe disruption to everyday life, with some 60% of young women saying that period pain causes them to cut back on their social or sporting activities8. And sporting activities themselves can cause significant incapacitation – a 1995 survey of sports and exercise-related injury estimated that 19.3 million new sports injuries occur in England & Wales alone every year9 - and this is likely to have increased since this last large-scale study was undertaken. Nearly half of these injuries (45%) are strains or sprains, with a further 18% classified as “unspecified pain”. A quarter of all injuries require medical treatment – most commonly from the family doctor, although 7% result in attendance at a hospital Accident & Emergency department.

- ends -


Notes to editors:
VIOXXâACUTE (rofecoxib) is licensed for the relief of acute pain and treatment of primary dysmenorrhoea, and is available on prescription in two strengths, an initial dose of rofecoxib 50mg once daily, following by subsequent doses of either 25 mg or 50 mg once daily as required.

Rofecoxib is the first of a new class of non-steroidal anti-inflammatory drugs (NSAIDs), COXIBs, to be available in the UK. It was initially designed to provide pain relief for osteoarthritis (OA) sufferers comparable to high dose NSAIDs, but with a significantly lower incidence of serious gastrointestinal (GI) events such as perforations, ulcers and bleeds10,11.


References:
1. Morrison B. Clin Ther 1999; 21(6): 943-953
2. Malmstrom K. Clin Ther 1999; 21(10): 1653-1663
3. Data on file, Merck Sharp & Dohme
4. Reicin A. Am J Orthopedics 2001; 40-48
5. Reuben SS. Anesth Analg 2000; 91: 1221-1225
6. Bonica JJ. The management of pain, 3rd ed. Philadelphia: Lea and Febigar, 1990: 222-254
7. Department of Health 1998. The Prevalence of Back Pain in Great Britain
8. Johnson J. J of Adolescent Healthcare 1988; 9: 398-402
9. Nicholl JP. Br J Sports Med vol 29, no 4, p 232-238
10. Hawkey, C.J. Lancet 1999, 353: 307–14
11. Langman MJ et al. JAMA 1999; 282: 1921-1928


For further media information, please contact:

Galliard Healthcare Communications
Ruth Ashton Nicole Barnard
tel: 020 7420 3287 tel: 020 7420 3284
mob: 07989 558041 email: nbarnard@galliardhealth.com
email: rashton@galliardhealth.com

Merck Sharp & Dohme Limited
Rachelle Michaels
tel: 01992 452470
mob: 07974 444402
email: rachelle_michaels@merck.com


For health professional and patients’ enquiries, please contact:

Merck Sharp & Dohme Limited
Medical Information Department
Tel: 01992 467272

Submitted by:
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.